Figure 1.

In the first step, patients with trichomoniasis were identified from the MarketScan outpatient services claims database using the ICD-10 codes for trichomoniasis (A59.00–.09, urogenital trichomoniasis; A59.8, trichomoniasis of other sites; and A59.9, trichomoniasis, unspecified). In the second step, we limited the analysis to outpatient claims where a patient received a single diagnosis (i.e., trichomoniasis diagnosis with no other ICD-10 codes), to ensure that costs unrelated to trichomoniasis were not included. In the third step, because of the lack of data on laboratory results, we limited the analysis to those with prescription drug treatment for trichomoniasis. In the fourth step, we limited the analysis to those patients with prescription drugs received within the same general time frame as the diagnosis. In the fifth step, we assumed that visits occurring within 30 days of the index visit were part of the same case. Costs occurring outside the 30-day window were assumed to be a subsequent case. In the final step, we limited the analysis to patients with no previous cases of trichomoniasis in the time frame we examined (2016–2018), although we performed a subanalysis on the costs associated with subsequent cases.